Chinese Government Venture Firm Funds JV To Explore Early-stage Oncology Trials
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- Texas-based South Texas Accelerated Research Therapeutics recently announced that it will partner with Shanghai-based venture capital fund Cenova Ventures to form a joint venture to conduct early-stage oncology trials for pharma companies on both sides of the Pacific
You may also be interested in...
China Builds Up Capability To Conduct Oncology First-In-Man Studies
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
China Builds Up Capability To Conduct Oncology First-In-Man Studies
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation
SHANGHAI - Jiangsu Hengrui Medicine Co. Ltd. seeks to transform itself from a generic company to an innovative one and tap into overseas markets. The move has prompted Chinese analysts to draw comparisons to the business models of Japan's largest pharma and to predict that Jiangsu Hengrui could become China's version of Takeda Pharmaceutical Co. Ltd.